Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.
Currently, there are no issues on this topic.